Indivior Pty

Risperidone is a small-molecule antipsychotic medication developed by Indivior Pty Ltd, indicated for schizophrenia. The program, identified as RB-US-09-0009, is currently in Phase 2 development status as of the latest milestone dated October 23, 2018. Risperidone is administered via intramuscular injection and is classified within the nervous system therapeutic category (ATC N05). The drug has achieved regulatory approval across multiple major markets, including the United States, European Union, Japan, China, and Australia, where it is marketed under the brand name APO-RISPERIDONE by multiple sponsors including Janssen-Cilag, Apotex, and Alphapharm. In the US market alone, risperidone has been approved through numerous abbreviated new drug applications (ANDAs) and new drug applications (NDAs), with over 50 approved formulations from diverse manufacturers including Indivior, Teva, Sandoz, Sun Pharma, and others. The intramuscular formulation represents a long-acting depot delivery approach, differentiating it from oral alternatives in the competitive antipsychotic landscape. Indivior's Phase 2 program reflects ongoing development efforts to optimize or expand the therapeutic profile of this established antipsychotic agent.

Schizophrenia remains a significant unmet medical need affecting approximately 1% of the global population, with substantial disease burden including cognitive dysfunction, negative symptoms, and high rates of treatment non-adherence. Long-acting injectable antipsychotics address a critical clinical challenge: medication non-compliance, which drives relapse rates and hospitalization. Intramuscular risperidone formulations offer extended dosing intervals, potentially improving adherence compared to daily oral regimens. The competitive antipsychotic market includes established agents such as INVEGA (paliperidone), ABILIFY (aripiprazole), REXULTI (brexpiprazole), and SAPHRIS (asenapine), representing a mature but clinically important therapeutic category. Risperidone's market relevance is sustained by its efficacy profile, tolerability data accumulated over decades, and cost-effectiveness as a generic or branded option across multiple healthcare systems. The large number of US-approved manufacturers (over 50 entities) indicates substantial commercial demand and market penetration. Indivior's continued Phase 2 development suggests potential optimization of formulation, dosing, or patient populations to maintain competitive positioning within the antipsychotic market. The patient population—individuals with schizophrenia requiring long-acting injectable therapy—represents a clinically vulnerable group with significant unmet needs for improved tolerability and efficacy profiles.

Drug Class: Atypical antipsychotic (second-generation antipsychotic)

Modality: Small molecule

Route of Administration: Intramuscular injection

Therapeutic Classification: Nervous system agents (ATC N05)

Brand Name: APO-RISPERIDONE

Mechanism of Action: Not yet disclosed in available program documentation

Target: Not yet disclosed in available program documentation

Related Therapies: Other long-acting injectable antipsychotics including paliperidone palmitate (INVEGA SUSTENNA), aripiprazole monohydrate (ABILIFY MAINTENA), and oral antipsychotics such as olanzapine, quetiapine, and lurasidone

First Approval History: Risperidone achieved initial regulatory approvals in Australia beginning November 1996. Subsequent approvals followed in Japan (February 2016), European Union (October 11, 2025), and the United States through multiple ANDA and NDA pathways. The drug is currently approved in China under clinical trial status as of the latest disclosed information.

Patent Status: Not yet disclosed

United States: Risperidone is approved via multiple pathways including NDA020272, NDA020588, NDA021346, NDA021444, NDA210655, NDA212849, NDA213586, and NDA214835, plus numerous ANDAs (ANDA076228 through ANDA218586). Over 50 US manufacturers hold approved applications, indicating broad market authorization and generic availability.

European Union: Approved under EMEA/H/C/005406 with marketing authorization holder Laboratorios Farmacéuticos Rovi, S.A., with authorization date October 11, 2025.

Japan (PMDA): Approved as of February 2016.

Australia (TGA): Approved with multiple PBS codes (11869Q, 11874Y, 11877D, 11879F, 11881H, 11882J, 14686Y, 14688C, 3169T, 3170W) across multiple sponsors including Alphapharm Pty Ltd, Apotex Pty Ltd, Arrow Pharma Pty Ltd, Generic Health Pty Ltd, and Janssen-Cilag Pty Ltd, with first listing November 1, 1996.

China (NMPA): Clinical trial status as of latest disclosure (NCT03510325); approval status not yet disclosed.

Expected Loss of Exclusivity Date: Not yet disclosed.

Strategic Positioning: Indivior's Phase 2 program for risperidone (RB-US-09-0009) represents continued investment in an established antipsychotic despite its mature market status. This suggests either formulation optimization (e.g., improved tolerability, extended dosing intervals), patient population expansion, or combination therapy development. The October 2018 milestone indicates active development, though no subsequent milestones have been publicly disclosed as of the latest data.

Competitive Implications: Risperidone faces intense generic competition with 50+ US manufacturers, limiting pricing power and market differentiation. Indivior's Phase 2 development likely targets value-added improvements rather than de novo efficacy claims. Long-acting injectable formulations remain clinically important for adherence-challenged populations, but INVEGA (paliperidone) and other newer agents have captured significant market share. Success depends on demonstrating clinical or commercial advantages over established competitors.

Regulatory and Commercial Catalysts: Completion of Phase 2 trials and potential Phase 3 initiation would represent key catalysts. Regulatory approvals in additional markets (particularly China, where clinical trials are ongoing) could expand addressable market. Label expansions for additional psychiatric indications (e.g., bipolar disorder, treatment-resistant schizophrenia) would represent significant commercial opportunities.

Future Milestones: Expected next milestones include Phase 2 trial completion, Phase 3 initiation (if warranted), and regulatory submissions in key markets. Timeline for these milestones is not yet disclosed.